Compare FuelCell Energy Inc (FCEL) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Novartis AG — how do they compare? FuelCell Energy Inc trades at $19.29 (market cap $1.59B), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG is far larger — about 187.5× FuelCell Energy Inc's market cap, and Novartis AG pays a 3.02% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals.
| FCEL | NVS | |
|---|---|---|
Market Cap | $1.59B | $298.18B |
Sector | Industrials | Health |
52-Week High | $36.01 | $168.62 |
52-Week Low | $3.92 | $118.55 |
Enterprise Value | $1.43B | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCEL trades at $20.43, up 0.54% today, near the analyst consensus target of $20.75. The stock shows a bearish technical signal with negative moving averages, while fundamentals reveal persistent losses: revenue grew to $158.16M in 2025 but net income margin was -132.41%. Recent news highlights partnerships with Siemens and AI data center demand as growth catalysts, though cash flow from operations remains negative at -$125.29M.
FCEL presents high-risk growth potential driven by alternative energy tailwinds and strategic alliances, but investment is speculative due to unprofitability, cash burn, and competitive pressures. Analysts are split evenly between Buy and Hold ratings, reflecting cautious optimism amid financial challenges. The stock's outlook hinges on execution toward profitability and scaling commercial projects.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
